Kazia Therapeutics Files 6-K for Q2 2023
Ticker: KZIA · Form: 6-K · Filed: Mar 27, 2024 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-update, biotech, licensing
Related Tickers: KZIA
TL;DR
Kazia Therapeutics (KZIA) filed its Q2 2023 6-K, showing financial updates and licensing info for Paxalisib & EVT801.
AI Summary
Kazia Therapeutics Ltd. filed a Form 6-K for the period ending December 31, 2023. The company, formerly Novogen Ltd., is based in Sydney, NSW, Australia. This filing provides financial information and updates related to its operations, including details on licensing agreements for its drug candidates, Paxalisib and EVT801.
Why It Matters
This filing provides investors with an update on Kazia Therapeutics' financial position and operational developments for the second quarter of fiscal year 2023, which is crucial for understanding the company's progress in its drug development pipeline.
Risk Assessment
Risk Level: medium — Biotech companies like Kazia Therapeutics carry inherent risks due to the nature of drug development, clinical trials, and regulatory approvals.
Key Players & Entities
- Kazia Therapeutics Ltd. (company) — Filer
- Novogen Ltd. (company) — Former company name
- Paxalisib (drug_candidate) — Licensing agreement
- EVT801 (drug_candidate) — Licensing agreement
FAQ
What is the reporting period for this 6-K filing?
The Conformed Period of Report is 20231231, indicating the period ending December 31, 2023.
What was Kazia Therapeutics Ltd. previously known as?
Kazia Therapeutics Ltd. was formerly known as Novogen Ltd., with a date of name change on 19981228.
Where is Kazia Therapeutics Ltd. headquartered?
The company's business and mail address is located at Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW, 2000.
What are some of the specific financial items mentioned in the filing's context?
The filing context mentions items such as Foreign Currency Translation Reserve, Other Reserves, Shares Subscribed But Unissued, Issued Capital, Retained Earnings, and Unlisted Options.
What licensing agreements are referenced in the filing's context?
The filing context references licensing agreements for Paxalisib and EVT801.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-03-27 08:26:45
Filing Documents
- d741878d6k.htm (6-K) — 82KB
- d741878dex991.htm (EX-99.1) — 667KB
- g741878g0313034236172.jpg (GRAPHIC) — 2KB
- g741878g0313034236482.jpg (GRAPHIC) — 2KB
- g741878g0313034236627.jpg (GRAPHIC) — 2KB
- g741878g0313034236789.jpg (GRAPHIC) — 2KB
- g741878g0313034236945.jpg (GRAPHIC) — 3KB
- g741878g0313034237270.jpg (GRAPHIC) — 2KB
- g741878g0313034237423.jpg (GRAPHIC) — 2KB
- 0001193125-24-078281.txt ( ) — 4345KB
- kzia-20231231.xsd (EX-101.SCH) — 67KB
- kzia-20231231_cal.xml (EX-101.CAL) — 25KB
- kzia-20231231_def.xml (EX-101.DEF) — 184KB
- kzia-20231231_lab.xml (EX-101.LAB) — 316KB
- kzia-20231231_pre.xml (EX-101.PRE) — 278KB
- d741878d6k_htm.xml (XML) — 697KB
From the Filing
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March , 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant's name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On March 27, 2024, Kazia Therapeutics Limited (th e "Comp any") reported its unaudited half-year results for the six months ended December 31, 2023, a copy of which is attached to this Form 6-K as Exhibit 99.1. The Company hereby incorporates by reference the information contained herein into the Company's registration statement on Form F-3 (File No. 333-259224 and 333-276091). EXHIBIT LIST Exhibit Description 99.1 Half-year report for the six months ended December 31, 2023 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: March 2 7 , 2024